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ABSTRACT
Dasatinib (DAS), a second-generation tyrosine kinase inhibitor, is highly effective 
in treating chronic myeloid leukemia and Philadelphia chromosome-positive acute 
lymphoblastic leukemia. However, its clinical use is limited due to serious adverse 
effects. DAS can disrupt endothelial barrier integrity and increase endothelial 
permeability which may cause peripheral edema and pleural effusion. Albumin 
nanoparticles (NPs) as a drug carrier may serve as a useful tool for cell-selective 
drug delivery to reduce DAS-induced endothelial hyperpermeability and maintain 
endothelial barrier integrity. In this study, we reported that DAS-loaded NPs exhibited 
potent anti-leukemia efficacy as DAS alone. Importantly, albumin NPs as a drug 
carrier markedly reduced DAS-induced endothelial hyperpermeability by restraining 
the inhibition of Lyn kinase signaling pathway in endothelial cells. Therefore, albumin 
NPs could be a potential tool to improve anti-leukemia efficacy of DAS through its 
cell-selective effects.
INTRODUCTION
Chronic myeloid leukemia (CML) and Philadelphia 
chromosome-positive acute lymphoblastic leukemia 
(ALL) are the most common types of leukemia with 
increasing morbidity [1–3]. Dasatinib (DAS), a small 
molecule tyrosine kinase inhibitor, can effectively fight 
against CML and ALL by inhibiting the activity of both Src 
and BCR-ABL tyrosine kinases in leukemia cells [4, 5]. 
However, DAS treatment has been reported to cause 
serious hematologic and non-hematologic adverse effects 
due to its interaction with non-disease-related processes 
and cells, which often leads to a dose reduction or 
treatment discontinuation in clinic [6]. Peripheral edema 
and pleural effusion are the common non-hematologic 
side effects occurred during DAS treatment, which is 
likely caused by endothelial hyperpermeability [7–9]. 
We reported previously that the basal activity of Lyn, 
a member of Src kinase family, is required to maintain 
endothelial barrier integrity [10]. Inhibition of Lyn kinase 
by DAS disrupts endothelial barrier integrity, resulting in 
increased endothelial permeability [10].
Nanoparticles (NPs) as a drug delivery system 
could enhance drug bioavailability, increase specificity, 
improve tissue selectivity and prolong pharmacological 
effect resulting in higher therapeutic efficacy [11–14]. 
Meanwhile, the adverse effects of drugs may be effectively 
eliminated by employing NPs as a drug carrier. Albumin 
NPs have become a promising carrier for drug delivery 
due to their merits in bioavailability, biocompatibility and 
biodegradability [15, 16]. It was reported that piceatannol-
loaded albumin NPs were able to prevent vascular 
inflammation by targeting activated neutrophils adherent 
to inflamed endothelium [17]. Albumin NPs loaded 
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with paclitaxel also exhibited an enhanced anti-tumor 
efficacy [18]. It was reported that albumin NPs were not 
internalized by the TNF-α-activated endothelium [17]. 
Avoiding direct interaction of DAS with Lyn 
kinase in endothelial cells may be a useful approach to 
prevent DAS-induced endothelial hyperpermeability. 
In this study, we investigated the possibility that the 
DAS-induced endothelial hyperpermeability could be 
prevented by employing albumin NPs as a drug carrier. 
Human leukemic K562 cells and human pulmonary artery 
endothelial cells (HPAECs) were used to investigate anti-
leukemia activity of DAS and DAS-loaded NPs, and their 
adverse effects on endothelial barrier function. Moreover, 
we investigated the effects DAS-loaded NPs on Lyn-
mediated cell signaling in endothelial cells, including 
Lyn phosphorylation, VE-cadherin localization, and focal 
adhesion kinase (FAK) modulation.
RESULTS
Characterization of albumin NPs
The results of dynamic light scattering showed 
that albumin NPs with and without DAS loading were 
similar in size and polydispersity index (PDI).The average 
diameter of DAS-loaded albumin NPs was 148.0 ± 0.5 nm, 
and the PDI was 0.163 ± 0.016 (Figure 1A). The Zeta 
Potential of DAS-loaded albumin NPs was −19.7 ± 1.4 mV 
(Figure 1B). After preparing the albumin NPs, the loading 
yield of DAS in albumin NPs was 10.4–15.1 wt%.
Effect of DAS and DAS-loaded NPs on leukemia 
cell viability
Our results showed that both DAS and DAS-
loaded NPs significantly inhibited the viability of K562 
cells compared to vehicle treated corresponding controls 
(Figure 2A). Furthermore, there was no significant 
difference in viability reduction between DAS and DAS-
loaded NPs treated cells. These results indicate that DAS-
loaded NPs possess the same anti-leukemia activity as DAS.
DAS is known to possess potent anti-leukemia 
activity through its inhibition of Src family kinases 
including Lyn [23–25]. To further assess the effects 
of DAS and DAS-loaded NPs on leukemia inhibition, 
phosphorylation levels of Lyn kinase (Figure 2B and 2C) 
and FAK (Figure 3) in K562 cells were evaluated 2 h after 
the treatment. DAS and DAS-loaded NPs significantly 
suppressed the phosphorylation of Lyn kinase, and the 
phosphorylation of FAK at residues Tyr397, Tyr576/577 
and Tyr925. There were no significant differences in the 
phosphorylation levels of Lyn kinase and FAK in K562 
cells between DAS and DAS-loaded NPs. These results 
indicate that the synthesized DAS-loaded NPs are as 
potent as DAS in leukemia inhibition.
Effect of DAS and DAS-loaded NPs on 
endothelial barrier function
To assess the effect of DAS and DAS-loaded NPs 
on endothelial barrier function, basal TER, an assay 
for endothelial barrier integrity, was measured at a 
different time points in HPAECs. Under the treatment of 
DAS, basal TER began to decrease from 0.5 h, reached 
its lowest point at 0.8 h (Figure 4), indicating that 
DAS-induced disruption of endothelial barrier integrity 
caused the increase of endothelial permeability. However, 
the treatment with DAS-loaded NPs had little effect on 
basal TER when compared with that of DAS. Our results 
indicate that albumin NPs as a drug carrier diminish 
endothelial barrier disruption caused by DAS. 
Effect of DAS and DAS-loaded NPs on adherent 
junctions in endothelial cells
The subcellular distribution of VE-cadherin, as 
a molecular marker of vascular endothelial adherent 
junctions, was examined in HPAECs monolayers to 
visualize the effect of DAS and DAS-loaded NPs on the 
integrity of endothelial junctions. DAS caused the distinct 
discontinuities in VE-cadherin distribution between 
the cells and formation of numerous interendothelial 
junctional gaps (White arrow) at 2 h, indicating the 
DAS disrupted adherent junction integrity (Figure 5). 
Interesting, DAS-loaded NPs had little effect on 
VE-cadherin distribution. The number of interendothelial 
junctional gaps was significantly decreased under the 
treatment of DAS-loaded NPs when compared with that 
of DAS-treated cells. The results further demonstrate that 
albumin NPs as a drug carrier retain endothelial barrier 
integrity.
Effect of DAS and DAS-loaded NPs on Lyn 
signaling in endothelial cells
We then examined the effect of DAS and DAS-
loaded NPs on Lyn kinase signaling in endothelial 
cells. DAS treatment significantly decreased the 
phosphorylation of Lyn kinase in HPAECs (Figure 6), 
while the treatment with DAS-loaded NPs had little effects 
on Lyn phosphorylation. These results indicated that DAS-
induced Lyn kinase inhibition was reduced by employing 
albumin NPs as drug carrier.
We previously reported that Lyn kinase-mediated 
regulation of FAK activity plays a pivotal role in 
maintaining endothelial barrier function [10]. To confirm 
the involvement of FAK in DAS-induced endothelial 
hyperpermeability, FAK expression was evaluated 
after the treatment with DAS and DAS-loaded NPs. In 
our study, DAS treatment significantly decreased the 
phosphorylation of FAK at residues Tyr576/577 and 
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Figure 1: Size (A) and Zeta potential (B) distribution of DAS-loaded albumin NPs. The size and Zeta potential distribution 
of DAS-loaded albumin NPs were measured. Data are representatives of three independent experiments.
Figure 2: Effects of DAS and DAS-loaded NPs on K562 cell viability and modulation of Lyn kinase. K562 cells were 
treated with DMSO, NPs, DAS (100 nM) or DAS-loaded NPs (DAS-NPs, 100 nM as DAS). (A) Cell viability was assessed by growth 
inhibition assay at 72 h after exposure. (B) Representative blots of phosphorylated Lyn (p-Lyn) and total Lyn (Lyn) kinases 2 h after the 
treatment. (C) Densitometry analysis is presented as relative ratios of p-Lyn to Lyn. Data were expressed as mean ± SEM. The experiments 
were repeated three times. *P < 0.05 versus DMSO group.
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Tyr925 without significantly affecting phosphorylation of 
FAK at residue Tyr397 (Figure 7). However, DAS-loaded 
NPs had little effects on FAK phosphorylation at residues 
Tyr576/577 and Tyr925 in HPAECs. Our results indicate 
that albumin NPs as a drug carrier reduce the inhibition 
of FAK-medicated signaling by DAS in endothelial cells.
Uptake of albumin NPs by leukemia cells and 
endothelial cells
To address the cell-selective effects of DAS NPs, 
we examined the uptake of Alexa Fluor 488 conjugated 
albumin NPs by K562 cells and HPAECs. Our results 
showed that Alexa Fluor 488-conjugated albumin NPs 
were efficiently internalized by K562 cells, while little 
green fluorescence was observed in HPAECs, indicating 
that albumin NPs failed to enter HPAECs (Figure 8). 
DISCUSSION
Adverse effects of anti-cancer drugs often lead to a 
dose reduction or discontinuation of treatments in clinical 
settings. NPs as a drug delivery system have been reported 
to serve as an effective approach to enhance the drug 
efficacy and reduce adverse effects [13]. Albumin NPs 
have been reported to serve as a promising drug carrier for 
treating inflammatory diseases and cancer [17, 18, 26, 27]. 
In this study, we successfully synthesized albumin NPs 
loaded with DAS.  Albumin NPs were prepared according 
to a modified desolvation method, which could assure 
DAS encapsulated in the NPs [19, 28]. DAS-loaded 
NPs possessed potent anti-leukemic activity as DAS. 
Importantly, albumin NPs as a drug carrier markedly 
reduced DAS-induced endothelial hyperpermeability by 
restraining the inhibition of Lyn-FAK signaling pathway.
In our study, the anti-leukemia activity of DAS and 
DAS-loaded NPs was assessed in K562 leukemia cells. 
Our results showed that DAS-loaded NPs possessed potent 
anti-leukemia activity as DAS. The key of NPs as a drug 
carrier lies in the successful uptake of drug-loaded NPs 
by target cells. It was reported that albumin NPs made 
from denatured albumin could be internalized by activated 
neutrophils [17]. DAS-loaded NPs may be internalized by 
K562 leukemia cells through FcγR [29]. DAS released 
from albumin NPs can then bind to Src and BCR-ABL 
tyrosine kinases and inhibit their autophosphorylation 
along with their downstream targets leading to blockade of 
the oncogenic activities of leukemia cells [30, 31]. Future 
studies using animal models of leukemia are needed to 
confirm our in vitro data. The in vivo studies could provide 
Figure 3: Effects of DAS and DAS-loaded NPs on FAK modulation in K562 cells. K562 cells were treated with DMSO, NPs, 
DAS (100 nM) or DAS-loaded NPs (DAS-NPs, 100 nM as DAS) for 2 h. (A) Representative blots of phosphorylated FAK (p-FAK-397, 
p-FAK-576/577 and p-FAK-925) and total FAK (FAK). (B–D) Densitometry analysis is presented as relative ratios of p-FAK-397, 
p-FAK-576/577 and p-FAK-925 to FAK. Data were expressed as mean ± SEM. The experiments were repeated three times. *P < 0.05 
versus DMSO group.
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important information on therapeutic potential of DAS-
loaded NPs.
We previously reported that inhibition of Lyn kinase 
disrupts endothelial barrier integrity [10]. Lyn, unlike 
other members of the Src kinase family including c-Src, 
Fyn, and Yes, strengthens endothelial barrier integrity 
through phosphorylation of FAK at residues Tyr576/577 
and Tyr925. FAK, a well-known Src family kinase (SFK) 
substrate, plays a critical role in maintaining endothelial 
barrier function [32, 33]. Down-regulation of FAK was 
reported to cause disruption of adherent junctions at 
endothelial borders resulting in formation of intercellular 
gaps [10], indicating that FAK plays an important role 
in re-establishing adherent junctions in endothelial cells. 
In addition, FAK is a major determinant of vascular 
permeability by regulating focal adhesion formation and 
turnover [34]. 
In this study, we demonstrated that DAS treatment 
disrupts endothelial barrier integrity in HPAECs by 
inhibiting Lyn-FAK signaling, which is characterized 
Figure 4: Effects of DAS and DAS-loaded NPs on TER across HPAECs. HPAECs were grown to confluence on gold 
microelectrodes arrays, then treated with DMSO, NPs, DAS (100 nM) or DAS-loaded NPs (DAS-NPs, 100 nM as DAS). TER across 
HPAECs monolayers was measured. (A) TER dynamic changes in 2.5 h. (B) Representative TER values at 0.8 h after exposure. (C) 
Representative TER values at 2.5 h after exposure. Data were expressed as mean ± SEM of four independent experiments. *P < 0.05 versus 
DMSO group; #P < 0.05 versus DAS group.
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Figure 5: Effects of DAS and DAS-loaded NPs on adherent junctions between HPAECs. HPAECs were treated with 
DMSO, NPs, DAS (100 nM) or DAS-loaded NPs (DAS-NPs, 100 nM as DAS) for 2 h. (A) Immunofluorescence staining for VE-cadherin 
subcellular distribution and formation of interendothelial junctional gaps (White arrow). Quantification of gaps (B) in 10 random images 
was expressed as mean ± SEM of three independent experiments. *P < 0.05 versus DMSO group; #P < 0.05 versus DAS group.
Figure 6: Effects of DAS and DAS-loaded NPs on Lyn signaling in HPAECs. HPAECs were treated with DMSO, NPs, DAS 
(100 nM) or DAS-loaded NPs (DAS-NPs, 100 nM as DAS) for 2 h. (A) Representative blots showing phosphorylated Lyn (p-Lyn) and 
total Lyn (Lyn) kinases. (B) Densitometry analysis is presented as relative ratios of p-Lyn to Lyn. Data were expressed as mean ± SEM. The 
experiments were repeated three times.*P < 0.05 versus DMSO group; #P < 0.05 versus DAS group. 
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by the formation of intercellular gaps between adjacent 
endothelial cells and reduced TER. The phosphorylation 
of endothelial Lyn and FAK was inhibited by DAS 
in endothelial cells. FAK phosphorylation at residues 
Tyr576/577 and Tyr925, not Tyr397, was also inhibited 
by DAS, which is consistent with our previous report 
on Lyn regulation of endothelial barrier function [10]. 
The subsequent vascular leakage due to endothelial 
hyperpermeability could lead to edema formation. 
Albumin NPs as a promising drug carrier could 
increase specificity and enhance therapeutic efficacy 
[17, 18]. Fluorescently tagged albumin NPs failed to 
Figure 7: Effects of DAS and DAS-loaded NPs on modulation of FAK in HPAECs. HPAECs were treated with DMSO, NPs, 
DAS (100 nM) or DAS-loaded NPs (DAS-NPs, 100 nM as DAS) for 2 h. (A) Representative blots showing phosphorylated (p-FAK-397, 
p-FAK-576/577 and p-FAK-925) and total FAK. (B–D) Densitometry analysis is presented as relative ratios of p-FAK-397, p-FAK-576/577 
and p-FAK-925 to FAK. Data were expressed as mean ± SEM. The experiments were repeated three times. *P < 0.05 versus DMSO group; 
#P < 0.05 versus DAS group. 
Figure 8: Uptake of albumin NPs by K562 and HPAECs. K562 cells and HPAECs were incubated with Alexa Fluor 488-conjugated 
albumin NPs for 2 h. Cells were then washed, fixed, and visualized by fluorescence microscopy. Images are representatives of three 
independent experiments. 
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be internalized by endothelial cells [17]. In our study, 
Albumin NPs entered leukemia cells efficiently, but 
exhibited little uptake by endothelial cells. The failed 
endocytosis of DAS-loaded NPs by HPAECs may be 
due to the lack of Fcγ receptors on endothelial cells [35]. 
Thus, the interaction of DAS with Lyn kinase in 
endothelial cells was prevented when DAS was loaded in 
albumin NPs. DAS-loaded NPs was not able to inhibit the 
phosphorylation of endothelial Lyn and FAK and had little 
effect on endothelial permeability. The adverse effects 
of DAS on endothelial barrier integrity were effectively 
eliminated by employing albumin NPs as a drug carrier. 
The albumin nanoparticles are designed by us to deliver 
DAS selectively to leukocytes with less toxicity to 
endothelial cells. It was also reported previously by others 
that piceatannol-loaded albumin NPs were able to inhibit 
vascular inflammation by targeting activated neutrophils 
adherent to endothelial cells [17]. The albumin NPs are 
not designed to be more selective to leukemia cells than to 
normal leukocytes yet. Hopefully, in the future we could 
also develop albumin NPs to selectively target leukemia 
cells and with less toxicity to normal leukocytes.
In summary, we have demonstrated that DAS-loaded 
albumin NPs exhibited potent anti-leukemia activity as 
DAS. The disruption of endothelial barrier integrity by 
DAS was markedly reduced by employing albumin NPs as 
drug carrier. DAS-loaded NPs may offer a new treatment 
option for patients with CML or Ph-positive ALL who 
are unable to tolerate DAS-induced edema and other 
fluid retention. Albumin NPs as a drug delivery system 
could improve the anti-leukemia efficacy of DAS through 
its cell-selective effects. DAS-loaded NPs are potential 
therapy for leukemia with better safety profile and anti-
leukemia efficacy. This study could help us improve 
the formulation of drugs with similar adverse effects as 
DAS. Further studies are warranted to assess the potential 
application of DAS-loaded albumin NPs in clinic.
MATERIALS AND METHODS
Materials
Human serum albumin (HSA, purity ≥ 99%) and 
8% glutaraldehyde solution were purchased from Sigma–
Aldrich Company (St. Louis, MO, USA). DAS (Purity: 
> 99%) was purchased from Cell Signaling Technology 
(Beverly, MA, USA). All other chemicals were purchased 
from Fisher Scientific (Pittsburgh, PA, USA). Rabbit 
polyclonal antibodies against phosphorylated FAK at 
residues Tyr397, 576/577, and 925, phosphorylated Lyn 
and total FAK, and a rabbit monoclonal antibody against 
total Lyn were obtained from Cell Signaling Technology 
(Beverly, MA, USA). A goat polyclonal antibody 
against VE-Cadherin was obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).
Synthesis and characterization of albumin NPs 
Albumin NPs were prepared according to a modified 
desolvation method [19]. Briefly, HSA was dissolved at 
a concentration of 20 mg/ml in 10 mM sodium chloride 
solution and the pH of the solution was titrated to 8. 
The resulting solutions were filtered through a 0.22 µm 
filtration unit (EMD Millipore Corporation, Billerica, 
MA, USA). To make DAS-loaded albumin NPs, HSA 
solution (1 ml) was incubated with 1 mg of DAS dissolved 
in DMSO for 1 h. Then, HSA solution (1 ml) with or 
without DAS co-incubation was transformed into NPs by 
the continuous addition of 4 ml of the desolvating agent 
methanol under stirring (550 rpm) at room temperature. 
The methanol addition was performed by a tubing pump 
(FH10, Thermo Fisher Scientific, Barrington, IL, USA) 
with a defined rate of 1 ml/min. After the desolvation 
process 24 µl of 8% glutaraldehyde in water were added 
to induce particle crosslinking. The crosslinking process 
was performed under stirring (200 rpm) of the suspension 
over a time period of 24 h at room temperature. The 
nanoparticle suspension was centrifuged at 14,000 rpm for 
30 min at 4°C. The nanoparticle pellet was re-suspended 
in phosphate-buffered saline (pH 7.4). 
The size and Zeta potential distribution of DAS-
loaded albumin NPs were measured using a Malvern 
Zetasizer Nano ZS Instrument (Malvern Instruments Ltd., 
Malvern, Worcestershire, UK). To evaluate the loading 
efficiency of DAS in albumin NPs, the supernatant 
(containing unbound DAS) after centrifugation of a 
suspension of DAS-loaded albumin NPs was collected 
and centrifuged using 10 kDa Microcon (EMD Millipore 
Corporation, Billerica, MA, USA) to separate unbound 
DAS (Molecular Weight: 488.01 Da) from free HSA 
(Molecular Weight: 66478 Da) molecules. DAS molecules 
in filtrate were quantified by measuring the absorbance at 
282 nm. The loading yield of DAS in albumin NPs was 
calculated with the following equation: loading yield 
(%) = (drug used–unloaded drug)/drug used. 
Cell culture 
Primary HPAECs were purchased from Lonza 
Walkersville Inc. (Conshohocken, PA, USA). These cells 
were cultured with endothelial growth medium-2 (EGM-2, 
Lonza Walkersville Inc.) and supplemented with 10% 
fetal bovine serum (FBS). Human leukemic K562 
cells (kindly provided by Dr. Ying Liang, University 
of Kentucky) were cultured with Iscove’s Modified 
Dulbecco’s Medium (IMDM, Thermo Scientific, Logan, 
UT, USA) supplemented with 10% heat-inactivated fetal 
bovine serum (FBS), penicillin and streptomycin (1%) 
and cultured at 37°C in a humidified incubator with 
5% CO2. 
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Growth inhibition assay
CellTiter 96 Aqueous Non-Radioactive cell 
proliferation Assay Kit (Promega Corp., Madison, 
Wisconsin, USA) was used for growth inhibition assay as 
previously described [20]. 10,000 K562 cells were plated 
in 96-well flat-bottomed plates and cultured for 24 h. 
Cells were exposed to DMSO, NPs, DAS (100 nM) or 
DAS-loaded NPs (100 nM as DAS) in IMDM with 10% 
FBS, for an additional 72 h. 20 μl MTS/PMS solution 
was added into each well containing 100 μl of the culture 
medium. Then, the cells were incubated for 3 h at 37°C 
before measurement of absorbance at 490 nm with an 
Epoch microplate spectrophotometer (BioTek Instruments 
Inc., Winooski, VT, USA). Absorbance values changes 
were normalized to that for untreated cells.
Measurement of transendothelial electrical 
resistance
Real-time changes in transendothelial electrical 
resistance (TER) across endothelial monolayers were 
measured to evaluate the endothelial barrier function as 
previously described [21]. Briefly, HPAECs were seeded 
onto gold microelectrode arrays (Applied Biophysics Inc., 
Troy, NY, USA) and cultured to confluence. Cells were 
exposed to DMSO, NPs, DAS (100 nM) or DAS-loaded 
NPs (100 nM as DAS). After exposure, impedance across 
the cells was measured for 2.5 h, and the TER changes 
were normalized to its initial value.
Immunofluorescence staining 
To assess the effect of DAS and DAS-loaded NPs 
on adherent junctions between endothelial cells, HPAECs 
cultured onto 0.2% gelatin-coated coverslips were 
incubated with DMSO, NPs, DAS (100 nM) or DAS-
loaded NPs (100 nM as DAS) for 2 h. Cells were fixed 
with 4% paraformaldehyde for 20 minutes, followed by 
permeabilization with 0.1% Triton ×-100. Thereafter, cells 
were incubated with primary antibody against endogenous 
VE-cadherin for 1 h, followed by incubation with Alexa-
Fluor 594 labeled donkey anti-goat secondary antibody, 
using Hanks balanced salt solution containing 1% 
bovine serum albumin as a blocking buffer. Images were 
acquired using an Olympus BX43 microscope (Olympus 
Corporation, Tokyo, Japan).
Cellular uptake of albumin NPs
Alexa Fluor 488 Protein Labeling Kit (Molecular 
Probes/Invitrogen, Eugene, OR, USA) was used to label 
albumin NPs. In brief, 0.5 ml of 2 mg/ml albumin NPs 
suspended in phosphate-buffered saline was mixed with 
50 µl of 1 M sodium bicarbonate solution. Then, the 
mixture was transferred to the provided vial of Alexa Fluor 
488 reactive dye and reacted for 1 h at room temperature. 
After reaction, the Alexa Fluor 488 conjugated albumin 
NPs were purified by three cycles of centrifugation 
(14,000 rpm for 30 min at 4°C) and re-suspended in 
phosphate-buffered saline. K562 cells were seeded onto 
24-well culture plates, with approximately 2.5 × 105 cells 
in 1 ml of medium. HPAECs were cultured onto 0.2% 
gelatin-coated coverslips placed in 24-well culture plates. 
K562 cells and HPAECs were cultured for 24 h, then 
exposed to the Alexa Fluor 488-conjugated albumin NPs 
(40 µg) for 2 h. The cells were washed three times with 
phosphate-buffered saline and fixed with –20°C 100% 
methanol for 10 minutes. After fixation, the cells were 
washed three times with phosphate-buffered saline. The 
coverslips with HPAECs were put on the slides coated 
with DAPI for nuclear staining. K562 cells were smeared 
on the surface of the slides and stained with DAPI. The 
uptake of albumin NPs by K562 cells and HPAECs was 
visualized using an Olympus BX43 microscope (Olympus 
Corporation, Tokyo, Japan).
Immunoblotting assay
Approximately 4 × 105 HPAECs or K562 cells were 
seeded into 6-well plates in serum-containing medium. 
After culture for 24 h, cells were exposed to DMSO, NPs, 
DAS (100 nM) or DAS-loaded NPs (100 nM as DAS) 
for 2 h. The cells were lysed for protein extraction using 
cell lysis buffer with protease inhibitor and phosphatase 
inhibitor (Cell Signaling Technology, Beverly, MA, USA). 
The total protein concentration was measured by BCA 
Protein Assay Kit (Pierce Biotechnology, Rockford, IL, 
USA). Isolated proteins (30 μg/Lane) were separated by 
SDS-PAGE and transferred to a polyvinylidene fluoride 
(PVDF) membrane for immunoblotting assay as described 
previously [22]. 
Statistical analyses
Statistics were performed using GraphPad Prism 6 
software (GraphPad Prism Software Inc., San Diego, CA, 
USA). Data were expressed as mean ± SEM. A one-way 
analysis of variance followed by Turkey’s test (multiple 
groups) was performed to determine the statistical 
significance (P < 0.05) between the indicated groups. 
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